In the News
Published on Benzinga, 19 February 2026
Biodexa Licenses Phase 1 Ready Drug Candidate
from Otsuka for Rare Stomach Cancer
MTX240’s mechanistic novelty may give it a long-awaited edge
in treatments for gastrointestinal stromal tumors (GIST
Published on Pharma Now, 3 December 2025
Biodexa Pharmaceuticals Begins European Enrollment In Phase 3 Serenta Trial As University Of Bonn Registers First Three Patients For eRapa In Familial Adenomatous Polyposis
Biodexa begins European enrollment in its Phase 3 Serenta trial of eRapa for FAP, advancing a potential non-surgical treatment option.
Published on Benzinga, 8 September 2025
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled Market
The first patients have now been enrolled into the Phase 3 Clincial Trial for FAP. This milestone has been published by Benzinga
Published on Clinical Trials Arena, 19 August 2025
First two subjects enrolled in Biodexa’s Phase III trial for FAP treatment
Biodexa Pharmaceuticals has enrolled the initial two subjects in the placebo-controlled Phase III Serenta study of an oral capsule formulation of rapamycin, eRapa, involving individuals with familial adenomatous polyposis (FAP).
Published on Benzinga, 28 July 2025
How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market
Our Phase 3 Clinical Trial is now underway and was covered by Benzinga in the following article
Published on Benzinga, 18 June 2025
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
Published on Pharmaceutial Technology, 13 May 2025
EC grants orphan drug status to Biodexa’s oral FAP treatment
This designation is a significant milestone for the company as it moves towards the final stages of implementing a Phase III study for eRapa.
Published on Benzinga, 19 March 2025
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter
Published on Benzinga, 12 February 2025
Following Positive Phase 2 Results And Orphan Drug Designation, Biodexa’s FAP Drug Receives FDA Fast Track Status
Published on Benzinga, 21 November 2024
Biodexa is Gaining Momentum, Advancing Two Recent Acquisitions Through the Clinic
Published on Benzinga, 17th October 2024
Biodexa’s MTX110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
Published on Benzinga, 11th July 2024
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa In Treatment Of Precancerous Polyps In The GI Tract – Now 12-Month Data
Published on Benzinga, 3rd June 2024
Promising Phase 2 Results For Biodexa’s eRapa™ Indicates Hope For FAP Patients Who Otherwise Have A 100% Lifetime Risk Of Colorectal Cancer
Published on Benzinga, 9th May 2024
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition
Published on Benzinga, 28th March 2024
Biodexa’s MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
